Director of Computational Biology — Lead Multi-Omics Targets (Hybrid/Remote)
Ionis Pharmaceuticals, Inc.
Boston (MA)
Hybrid
USD 200,385 - 250,332
Full time
14 days+
A complete application in a minute
Tailored resume and cover letter, ready to send.
Get past ATS filters
Benefits offered by this job
Excellent benefits package
Job summary
Ionis Pharmaceuticals, Inc. is seeking a Director of Computational Biology in Boston to lead target identification and multi-omics research. This role requires a PhD and 8+ years of experience in the field, with a proven track record in multi-omics approaches. Responsibilities include developing analytical pipelines and managing a team of computational biologists. The position offers a competitive salary range of $200,385 to $250,332 and excellent benefits, fostering an innovative work environment focused on advancing RNA-targeted medicines.
Qualifications
8+ years of relevant experience in computational biology or bioinformatics.
Proven experience in target identification using multi-omics approaches.
Methodological breadth in statistical modeling and deep learning.
Responsibilities
Lead the development of target identification pipeline using multi-omics data.
Evaluate cross-species conservation and translational risk.
Develop and maintain analytical pipelines with best practices.
Skills
Multi-omics analysis
Data integration
Python programming
R programming
Communication skills
Education
PhD in computational biology or related field
Tools
Bash
Docker
Nextflow
AWS
Job description
Ionis Pharmaceuticals, Inc. is seeking a Director of Computational Biology in Boston to lead target identification and multi-omics research. This role requires a PhD and 8+ years of experience in the field, with a proven track record in multi-omics approaches. Responsibilities include developing analytical pipelines and managing a team of computational biologists. The position offers a competitive salary range of $200,385 to $250,332 and excellent benefits, fostering an innovative work environment focused on advancing RNA-targeted medicines.